Navigation Links
Renal Advantage and Liberty Dialysis Deal Completed

FRANKLIN, Tenn. and MERCER ISLAND, Wash., Dec. 22, 2010 /PRNewswire/ -- Renal Advantage and Liberty Dialysis, which last month agreed to combine to form the third largest provider of dialysis services in the U.S., today announced that they have closed their deal.  The transaction – terms of which were not disclosed – was completed on December 17, 2010.  The combined organization has 5,300 employees serving more than 19,000 patients in 260 locations in 32 states.

"The completion of our deal signals a new era in the dialysis industry, uniting two patient-focused, physician driven and employee-oriented companies with great autonomy to build their brands," said Mark Caputo, founder of Liberty Dialysis and CEO of the combined organization.  "This transaction allows us to take advantage of the combined financial strength, purchasing power, and systems investment of two leaders in the industry."  

"As we begin a new year with change on the health care horizon, we are well positioned for robust growth in the future through this deal," said Michael D. Klein, who has served as chief executive officer of RAI. "By focusing on the patient, partnering with talented nephrologists, and recruiting the best caregivers, we will optimize patient outcomes through active participation of both patients and caregivers."

Liberty Dialysis has been among the fastest growing dialysis companies for each of the last eight years, achieving 25 percent annual growth rates.  Similarly, RAI has nearly doubled in size since its inception over five years ago.  To accommodate its rapid growth, RAI has moved into a new 54,000 square foot office building in the McEwen Building in Franklin, Tenn., a suburb of Nashville.  RAI will consolidate its existing corporate offices into this one location, improving efficiency while providing for its growth needs for the future. Liberty's existing administrative offices in conjunction with RAI's are forming a shared services organization supporting the two sister companies.  

About Liberty DialysisWith more than 112 dialysis clinics, Liberty Dialysis, is dedicated to providing outstanding care for patients with kidney disease, and a rewarding career experience for its caregivers.  Liberty has a history of developing clinics in underserved communities in conjunction with local physicians and non-profit organizations.  Liberty partners with local nephrologists and hospitals in developing, owning and operating these centers.  Liberty was founded in 2002 by Mark Caputo and Bob Santelli in conjunction with Bain Capital.  Liberty's historic rapid growth has been funded, in part, by subsequent equity investments from Bain Capital, KRG Capital Partners, and Ignition Partners, each of whom will continue as equity sponsors of the merged organization.  For more information on the company, please visit the website for Liberty Dialysis at

Barclays Capital and Bank of America Merrill Lynch served as financial advisors to Liberty Dialysis Holdings, Inc in relation to its transaction with RAI.

About Renal AdvantageBased in Brentwood, Tenn., Renal Advantage provides dialysis services to patients with chronic kidney failure, also known as end-stage renal disease (ESRD). Renal Advantage and Liberty Dialysis recently announced their merger which clearly positions the combined organization as the third largest provider of dialysis services in the U.S.  The shared services organization will maintain their unique brands in the markets they serve, and have 5,300 employees serving more than 19,000 patients in 260 locations in 32 states.  RAI also advances pioneering laboratory services through RenaLab, a state-of-the-art independent clinical laboratory located in Jackson, Miss.  Founded by veteran healthcare executives, RAI's growth plan began with its acquisition of 73 dialysis centers in October 2005.   For more information, visit RAI's website at

Raymond James & Associates and Moelis & Company served as financial advisors to Renal Advantage in relation to this merger.Contact:

Todd Smith (M) 615.202.7944 (O)

SOURCE Renal Advantage
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
2. The Renal Anemia Market Shows Signs of Stabilization but Changes are Occurring in the Bone and Mineral Metabolism Market
3. Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures
4. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
5. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
6. New Report by BioTrends Examines the Treatment of Renal Anemia in China
7. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
8. Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
9. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
10. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
11. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... -- --> --> Juntendo ... optimal contrast weighting of MRI for patients with Multiple ... research agreement with SyntheticMR in order to use SyMRI in ... possible to generate multiple contrast images from a single scan ... thus making it possible to both fine tune images and ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... , ... Smiles by Stevens is pleased to announce the addition ... many patients are aware of the benefits of Botox® in the treatment of moderate ... with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
Breaking Medicine News(10 mins):